MedTrace Logo

Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

NCT02265666 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2014-10-16

No results posted yet for this study

Summary

The objective of the present study is to investigate the relative bioavailability of BIIL 284 BS Tablet FF in comparison to the tablet C at a dose of 5 mg after a standard breakfast in healthy male volunteers

Conditions

  • Healthy

Interventions

DRUG

BIIL 284 BS Tablet FF

DRUG

BIIL 284 BS tablet C

OTHER

standard breakfast

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-10-31
Primary Completion
2001-11-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02265666 on ClinicalTrials.gov